To The Moon

$Novartis AG(NVS)$ upcoming fiscal Q3 2025 earnings is scheduled to be reported before the market opens on Tuesday, October 28, 2025.

Q3 2025 Consensus Estimates

These are the headline numbers Wall Street will be measuring the report against. A "beat" or "miss" on these two metrics will set the initial tone for the stock's reaction.

Consensus EPS: $2.26 (representing an approximate 9.7% increase year-over-year)

Consensus Revenue: $13.90 billion (representing an approximate 8.4% increase year-over-year)

Novartis has a strong recent history of beating EPS estimates, so a simple beat may already be priced in. The magnitude of the beat and, more importantly, the quality of it (i.e., driven by sales growth vs. cost control) will be key.

Summary of Q2 2025 Earnings

Novartis delivered a very strong "beat and raise" quarter in Q2 2025, demonstrating significant underlying business momentum. The results showcased the successful transition of its growth narrative from its maturing blockbuster, Entresto, to its new portfolio of high-growth "priority brands."

Headline Financial Performance:

Core EPS: $2.42 (a 24% increase in constant currency), beating the analyst consensus of $2.38.

Net Sales: $14.05 billion (a 12% increase in USD, 11% in constant currency), beating the consensus of $13.94 billion.

Core Operating Income: Grew 21% (in constant currency), leading to a significant core margin expansion of 340 basis points to 42.2%.

Key Performance Drivers:

The quarter's strength was not driven by one-offs but by the exceptional sales of its new growth drivers. The "priority brands" portfolio grew 30% (in constant currency).

Kisqali (Oncology): This was the star of the show. Sales grew an explosive 64% (cc) to $1.18 billion, driven by its new approval for early breast cancer, where it is rapidly capturing market share.

Pluvicto (Oncology): The radioligand therapy returned to robust growth, jumping 30% (cc) as supply constraints eased and it benefited from approval in the pre-taxane setting.

Kesimpta (Neuroscience): Continued its strong performance in multiple sclerosis, with sales up 33% (cc) to $1.08 billion.

Leqvio & Scemblix: These newer launches also posted very strong growth, up 61% (cc) and 79% (cc), respectively, confirming their blockbuster potential.

Entresto (Cardiovascular): The established blockbuster still performed well, growing 22% (cc) to $2.36 billion.

The Key Lesson from the Q2 Guidance

The most important lesson from the Q2 2025 earnings report was: The new growth portfolio is strong enough to allow the company to raise its profit outlook while simultaneously absorbing the long-feared "patent cliff" of its biggest drug, Entresto.

Here is a breakdown of the guidance and the lesson it teaches:

What Was the Guidance?

Sales Guidance (Reaffirmed): Management reaffirmed its full-year 2025 sales growth forecast to be in the "high single-digit" range.

Profit Guidance (Raised): Management raised its full-year 2025 core operating income growth forecast from "low double-digit" to "low teens."

The "Entresto Assumption" (The Fine Print): The most critical piece of the guidance was a new "key assumption." Novartis explicitly stated that its financial forecast now assumes the "US entry of Entresto generics in mid-2025."

Analysis of the Lesson:

For years, the biggest risk hanging over the Novartis stock has been the eventual loss of exclusivity (LOE) for its multi-billion dollar heart failure drug, Entresto. The Q2 2025 report was the moment management officially "pulled forward" this risk, moving it from a distant threat to a concrete financial assumption.

Normally, a company confirming its biggest product will face generic competition this year would cause the stock to fall, or at least lead to a guidance cut.

Instead, Novartis did the exact opposite: it raised its profit guidance.

This sent a powerful message to the market: the "replacement power" of Kisqali, Pluvicto, and Kesimpta is not just a theory; it is happening faster and more effectively than anticipated. Their combined growth is so strong that it can completely offset the initial impact of the Entresto patent cliff and still allow for significant margin expansion and profit growth for the full year.

In short, the lesson from the Q2 guidance was one of confident transition. It signaled that the Entresto headwind, while real, is now a manageable problem that is already baked into the company's financial model, allowing investors to focus on the powerful and durable growth of the new portfolio.

Key Metrics & Narratives for Investors to Watch

Beyond the headline numbers, the long-term value of Novartis is in its drug portfolio and pipeline. Here is what investors will be scrutinizing:

Full-Year 2025 Guidance (The Most Important Metric)

This is often the primary driver of the stock's post-earnings move.

• Current Guidance: After a strong Q1, Novartis raised its full-year 2025 guidance to "high single-digit" sales growth and "low double-digit" core operating income growth.

• What to Watch: The stock is trading near its 52-week high, meaning expectations are elevated. A simple reaffirmation of this guidance might be viewed as a disappointment. Investors will be looking for another guidance raise, (e.g., to "low double-digit" sales or "mid-teens" core operating income) to justify the stock's current valuation.

Key Drug Sales Performance (The "Growth Drivers")

Novartis's growth is concentrated in a few key "priority" drugs. Their individual performance is critical.

• Kisqali (Oncology): This is arguably the most-watched drug. Analyst consensus suggests staggering growth, with sales expected to hit $1.29 billion for the quarter, a +64.2% year-over-year jump. This is driven by its expansion into the early breast cancer market. A miss here would be a major negative.

• Pluvicto (Oncology): This radioligand therapy is another key growth engine. Investors will be looking for continued robust sales growth and, importantly, management commentary on the recent positive Phase III (PSMAddition) data presented at the ESMO 2025 congress, which showed its effectiveness in earlier-stage (mHSPC) prostate cancer.

• Entresto (Cardiovascular): This remains a massive cash cow. However, a major patent cliff looms. Management's current guidance assumes US generic competition starting in mid-2025. Any change to this timeline—either a delay (highly positive) or an acceleration (highly negative)—will cause a significant stock reaction.

• Kesimpta (Neuroscience): This multiple sclerosis drug is a consistent performer. Look for continued market share gains, as it has been leading in new-to-brand (NBRx) prescriptions.

• Cosentyx (Immunology): This is a more mature blockbuster. Growth has moderated, with analysts expecting a modest +1.9% increase. The focus is on whether it can defend its market share against new competitors.

Pipeline and Margin Commentary

• Core Operating Margin: Novartis has delivered strong margin expansion. Investors will check if this continues, or if increased R&D and marketing spend (for its new drug launches) is beginning to eat into profitability.

• Pipeline Updates: Besides Pluvicto, any updates on other key late-stage assets, such as remibrutinib, will be closely watched for future growth.

Novartis (NVS) Price Target

Based on 10 analysts from Tiger Brokers offering 12 month price targets for Novartis in the last 3 months. The average price target is $119.63 with a high forecast of $142.00 and a low forecast of $100.00. The average price target represents a -9.12% change from the last price of $131.64.

Potential Short-Term Post-Earnings Trading Opportunities

Post-earnings trading is driven by volatility, which arises when the reported results differ from expectations. Here are the key "push and pull" factors that could create a short-term trading opportunity:

The Bull Case (Opportunity for a Breakout):

• Scenario: Novartis delivers a "beat and raise"—topping the $2.26 EPS / $13.90B revenue estimates and raising its full-year 2025 guidance.

• Catalysts: This would likely be driven by a massive beat from Kisqali (well above the +64.2% expectation) and any positive commentary delaying the Entresto generic timeline. With the stock near 52-week highs, this is the "clean" scenario needed for a rally to new highs.

The Bear Case (Opportunity for a Pullback):

• Scenario 1 (The "Guidance Trap"): Novartis beats Q3 estimates but only reaffirms its full-year guidance. Given the stock's high price, this could trigger a "sell the news" event as traders who expected a raise take profits.

• Scenario 2 (The "Growth Miss"): Novartis misses on a key growth driver. Any sign of a slowdown in Kisqali or Pluvicto would be punished severely, as these drugs are the foundation of the company's future growth narrative.

• Scenario 3 (The "Patent Cliff"): Any negative news on the Entresto patent cliff (e.g., generics coming sooner than mid-2025) would overshadow any positive Q3 results and likely cause a sharp sell-off.

Overall Sentiment: The consensus analyst rating on NVS is currently a "Hold". This mixed sentiment suggests the market is in a "wait and see" mode, which can amplify a move in either direction once the Q3 results and, most importantly, the updated guidance are released.

Technical Analysis - Exponential Moving Average (EMA)

If we looked at how NVS have been trading over the past weeks, we can see that it is actually consolidating, and the bulls are trying to push for a higher upside, but concerns over drugs moderation and decline might deter investors to get in.

Analysts have given a “hold” rating for this stock, so we might want to look at how NVS is trading today (24 Oct) and on Monday (27 Oct), to see if there is any signs that there might be an earnings surprise that could push the share price higher.

Summary

Novartis (NVS) is generally expected to report solid results for fiscal Q3 2025, driven by momentum in key products.

 Q3 2025 Consensus Estimates

Earnings Per Share (EPS): Analysts project $2.26 to $2.28 per share, which would represent a year-over-year increase of around 9.7% to 18.8% compared to Q3 2024's reported $2.06.

 Revenue: Consensus revenue forecasts are between $13.7 billion and $13.9 billion, suggesting an increase of approximately 7% to 8.4% compared to the prior year's $12.82 billion.

Key Growth Drivers

Growth is anticipated to be fueled by strong sales from key innovative medicines, particularly Kisqali (expected to see very high growth), Leqvio, Kesimpta, and Scemblix. However, some mature brands like Cosentyx and certain oncology drugs face moderation or declines, which could temper overall growth.

Analyst Sentiment

Overall analyst sentiment is "Hold" with a mix of ratings, suggesting expectations for continued but controlled growth, with a potential stock price target slightly below the current trading price. The company's prior quarter performance beat expectations, which factors into the optimistic outlook for Q3.

Appreciate if you could share your thoughts in the comment section whether you think NVS could navigate the headwinds of drugs moderation and declines, and move towards controlled growth.

@TigerStars @Daily_Discussion @Tiger_Earnings @TigerWire @MillionaireTiger appreciate if you could feature this article so that fellow tiger would benefit from my investing and trading thoughts.

Disclaimer: The analysis and result presented does not recommend or suggest any investing in the said stock. This is purely for Analysis.